Good morning, it's Paul & Jack here with the SCVR for Monday.

Agenda -

Paul's Section:

Preamble on supply chains & inflation.

Tristel (LON:TSTL) - a quick look at FY 6/2021 results & outlook. After a "disappointing year" the outlook sees business returning to normal, and growth resuming. It's a nice little company, but I question the high valuation - it will need to seriously beat current forecasts, to justify the current share.

Supreme (LON:SUP) (I hold) - a reassuring trading update today, from this entrepreneurial company. It seems to hint at possible out-performance later this financial year? Valuation looks modest, and with good quality scores too. Looks good to me.

Jack's Section:

Centralnic (LON:CNIC) - profit to be at the upper end of guidance, with an improving organic growth trajectory. The valuation is modest relative to peers and the apparent growth prospects, but integrating multiple acquisitions while steering organic growth is tricky. Management is so far proving up to the task.

Mind Gym (LON:MIND) - revenue has returned more or less to pre-pandemic levels but the share price has risen faster than profits have recovered. The high valuation combined with a lack of share price liquidity is enough to keep me on the sidelines.

Bioventix (LON:BVXP) - a quick look over results for FY 06/2021. This is a remarkable little company, making a staggering profit margin for its niche disgnostic products (antibodies). Specialist knowledge is needed to assess this company's prospects/value, hence I'm neutral on it.

Explanatory notes -

A quick reminder that we don’t recommend any stocks. We aim to cover trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.

We stick to companies that have issued news on the day, with market caps up to about £700m. We avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).

A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here